The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program.
Drug: Bamlanivimab
Administered intravenously (IV).
Other Name: Array
Inclusion Criteria:
- Reside in a country where there are ongoing Lilly-sponsored clinical trials (currently
this is only the United States)
- Present within 10 days of symptom onset
- Have severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) confirmed by reverse
transcription polymerase chain reaction (RT-PCR) within the last three days
- Participants greater than or equal to (≥) 65 years of age OR
- Participants ≥ 12 years of age who weigh at least 40 kilograms AND have at least one
of the following:
- Cancer
- Chronic kidney disease
- Chronic obstructive pulmonary disease (COPD) or other chronic lung disease
- Immunocompromised state (weakened immune system or on immunomodulatory
medications)
- Obesity (body mass index [BMI] of 35 or higher)
- Serious heart conditions such as heart failure, coronary artery disease or
cardiomyopathies
- Sickle cell disease
- Diabetes mellitus (Types 1 or 2)
Exclusion Criteria:
- Require hospitalization greater than (>) 24 hours or hospice care. Residents in long
term care or skilled nursing facilities that meet the inclusion criteria and are not
on mechanical ventilation will be considered
- Bamlanivimab should not be used in patients hospitalized with severe COVID-19
respiratory disease
Contact Lilly at 1-800-LillyRx (1-800-545-5979), Study Director
Eli Lilly and Company